{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T16:37:26Z","timestamp":1768667846625,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41375-018-0247-1","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T14:06:00Z","timestamp":1536588360000},"page":"2095-2104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-9597","authenticated-orcid":false,"given":"Nazanin","family":"Aghel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Hernan","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey Howard","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"247_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27325849\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"247_CR2","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210\u20138. \n                    http:\/\/jco.ascopubs.org\/cgi\/doi\/10.1200\/JCO.2015.62.4718\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"247_CR3","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457\u201367. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27732808\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"247_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","volume":"66","author":"W Li","year":"2015","unstructured":"Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies. J Am Coll Cardiol. 2015;66:1160\u201378. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26337996\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"key":"247_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/ejh.12096","volume":"90","author":"L Levato","year":"2013","unstructured":"Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013;90:531\u20132. \n                    http:\/\/doi.wiley.com\/10.1111\/ejh.12096\n                    \n                  .","journal-title":"Eur J Haematol"},{"key":"247_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3324\/haematol.2011.058776","volume":"97","author":"TD Kim","year":"2012","unstructured":"Kim TD, le Coutre P, Schwarz M, Grille P, Levitin M, Fateh-Moghadam S, et al. Clinical cardiac safety profile of nilotinib. Haematologica. 2012;97:883\u20139. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22271904\n                    \n                  .","journal-title":"Haematologica"},{"key":"247_CR7","unstructured":"ICLUSIG\u00ae (ponatinib). \n                    http:\/\/www.iclusig.com\/hcp\/\n                    \n                  ."},{"key":"247_CR8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783\u201396. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24180494\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"247_CR9","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:612\u201321. \n                    http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204516000802\n                    \n                  .","journal-title":"Lancet Oncol"},{"key":"247_CR10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.cjca.2016.04.008","volume":"32","author":"CB Johnson","year":"2016","unstructured":"Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol. 2016;32:900\u20137. \n                    http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X16300526\n                    \n                  .","journal-title":"Can J Cardiol"},{"key":"247_CR11","unstructured":"CTCAE Files.\n                     https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html"},{"key":"247_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"KA Hicks","year":"2015","unstructured":"Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials. J Am Coll Cardiol. 2015;66:403\u201369. \n                    http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109714074841\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"key":"247_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","volume":"137","author":"KA Hicks","year":"2018","unstructured":"Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al.Cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961\u201372. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29483172\n                    \n                  .","journal-title":"Circulation"},{"key":"247_CR14","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1016\/j.jacc.2015.10.036","volume":"66","author":"SJ Pocock","year":"2015","unstructured":"Pocock SJ, Clayton TC, Stone GW. Design of major randomized trials. J Am Coll Cardiol. 2015;66:2757\u201366. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26700838\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"key":"247_CR15","doi-asserted-by":"publisher","first-page":"e41174","DOI":"10.1371\/journal.pone.0041174","volume":"7","author":"JB Schroll","year":"2012","unstructured":"Schroll JB, Maund E, G\u00f8tzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS One. 2012;7:e41174.","journal-title":"PLoS One"},{"key":"247_CR16","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Mauro MJ, Hong F, Ortmann C-E, McNeill C, Woodman RC, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia [Internet]. 2013;27:1310\u20135. \n                    http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2013.69\n                    \n                  .","journal-title":"Leukemia [Internet]"},{"key":"247_CR17","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316\u201321. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23459449\n                    \n                  .","journal-title":"Leukemia"},{"key":"247_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1200\/JCO.2013.52.2219","volume":"32","author":"S Sivendran","year":"2014","unstructured":"Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014;32:83\u20139. \n                    http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2013.52.2219\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"247_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ejhf.457","volume":"18","author":"M Vaduganathan","year":"2016","unstructured":"Vaduganathan M, Prasad V. Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. Eur J Heart Fail. 2016;18:128\u201332. \n                    http:\/\/doi.wiley.com\/10.1002\/ejhf.457\n                    \n                  .","journal-title":"Eur J Heart Fail"},{"key":"247_CR20","unstructured":"Fda. Guidance for industry diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. \n                    http:\/\/www.fda.gov\/cder\/guidance\/index.htm\n                    \n                  ."},{"key":"247_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699\u2013708. \n                    http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1105819\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"247_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D'Agostino","year":"2008","unstructured":"D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743\u201353. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18212285\n                    \n                  .","journal-title":"Circulation"},{"key":"247_CR23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (London, England). 2004;364:937\u201352. \n                    http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673604170189\n                    \n                  .","journal-title":"Lancet (London, England)"},{"key":"247_CR24","doi-asserted-by":"crossref","unstructured":"The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41:105\u201314. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3335877\n                    \n                  .","DOI":"10.1016\/0895-4356(88)90084-4"},{"key":"247_CR25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/eurheartj\/14.5.584","volume":"14","author":"E Sigurdsson","year":"1993","unstructured":"Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Prevalence of coronary heart disease in Icelandic men 1968\u20131986. The Reykjavik Study. Eur Heart J. 1993;14:584\u201391. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8508850\n                    \n                  .","journal-title":"Eur Heart J"},{"key":"247_CR26","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2337\/dc10-0245","volume":"33","author":"J Liu","year":"2010","unstructured":"Liu J, Fox CS, Hickson D, Sarpong D, Ekunwe L, May WD, et al. Pericardial adipose tissue, atherosclerosis, and cardiovascular disease risk factors: the Jackson Heart Study. Diabetes Care. 2010;33:1635\u20139. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20413524\n                    \n                  .","journal-title":"Diabetes Care"},{"key":"247_CR27","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djr292","volume":"103","author":"P Coutre Le","year":"2011","unstructured":"Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103:1347\u20138. \n                    https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djr292\n                    \n                  .","journal-title":"J Natl Cancer Inst"},{"key":"247_CR28","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26837842\n                    \n                  .","journal-title":"Leukemia"},{"key":"247_CR29","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","volume":"17","author":"N Aghel","year":"2017","unstructured":"Aghel N, Lipton JH, Atenafu EG, Kim DDH, Delgado DH. Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up. Clin Lymphoma Myeloma Leuk. 2017;17:870\u2013878.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"247_CR30","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics\u20192017 update: a report from the American Heart Association. Circulation. 2017;135:e146\u2013603.","journal-title":"Circulation"},{"key":"247_CR31","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","volume":"297","author":"PG Steg","year":"2007","unstructured":"Steg PG, Bhatt DL, Wilson PWF, D\u2019Agostino R, Ohman EM, R\u00f6ther J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197. \n                    http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.297.11.1197\n                    \n                  .","journal-title":"JAMA"},{"key":"247_CR32","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20805624\n                    \n                  .","journal-title":"JAMA"},{"key":"247_CR33","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163\u201370. \n                    https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehu505","journal-title":"Eur Heart J"},{"key":"247_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.recesp.2015.06.016","volume":"69","author":"E Abu-Assi","year":"2016","unstructured":"Abu-Assi E, L\u00f3pez-L\u00f3pez A, Gonz\u00e1lez-Salvado V, Redondo-Di\u00e9guez A, Pe\u00f1a-Gil C, Bouzas-Cruz N, et al. The risk of cardiovascular events after an acute coronary event remains high, especially during the first year, despite revascularization. Rev Esp Cardiol (Engl Ed). 2016;69:11\u20138. \n                    http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585715002704","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"247_CR35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.clml.2015.09.008","volume":"15","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on national comprehensive network treatment guidelines. Clin Lymphoma Myeloma Leuk. 2015;15:797\u2013802.e1. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26603185\n                    \n                  .","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"247_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FGR Fowkes","year":"2013","unstructured":"Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329\u201340. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23915883\n                    \n                  .","journal-title":"Lancet"},{"key":"247_CR37","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.108.191171","volume":"118","author":"WR Hiatt","year":"2008","unstructured":"Hiatt WR, Goldstone J, Smith SC, McDermott M, Moneta G, Oka R, et al. Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation. 2008;118:2826\u20139. \n                    http:\/\/circ.ahajournals.org\/cgi\/doi\/10.1161\/CIRCULATIONAHA.108.191171\n                    \n                  .","journal-title":"Circulation"},{"key":"247_CR38","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","volume":"116","author":"MH Criqui","year":"2015","unstructured":"Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509\u201326. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25908725\n                    \n                  .","journal-title":"Circ Res"},{"key":"247_CR39","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1161\/01.CIR.0000137913.26087.F0","volume":"110","author":"E Selvin","year":"2004","unstructured":"Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999\u20132000. Circulation. 2004;110:738\u201343. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15262830\n                    \n                  .","journal-title":"Circulation"},{"key":"247_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/0003319707302494","volume":"58","author":"P Poredos","year":"2007","unstructured":"Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology. 2007;58:309\u201315. \n                    http:\/\/ang.sagepub.com\/cgi\/doi\/10.1177\/0003319707302494\n                    \n                  .","journal-title":"Angiology"},{"key":"247_CR41","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1161\/CIRCULATIONAHA.114.011021","volume":"130","author":"S Subherwal","year":"2014","unstructured":"Subherwal S, Patel MR, Chiswell K, Tidemann-Miller BA, Jones WS, Conte MS, et al. Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. Circulation. 2014;130:1812\u20139. \n                    http:\/\/circ.ahajournals.org\/cgi\/doi\/10.1161\/CIRCULATIONAHA.114.011021\n                    \n                  .","journal-title":"Circulation"},{"key":"247_CR42","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.115.016424","volume":"132","author":"DPJ Howard","year":"2015","unstructured":"Howard DPJ, Banerjee A, Fairhead JF, Hands L, Silver LE, Rothwell PM, et al. Population-based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention. Circulation. 2015;132:1805\u201315. \n                    http:\/\/circ.ahajournals.org\/lookup\/doi\/10.1161\/CIRCULATIONAHA.115.016424\n                    \n                  .","journal-title":"Circulation"},{"key":"247_CR43","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","volume":"126","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020\u201335. \n                    http:\/\/circ.ahajournals.org\/cgi\/doi\/10.1161\/CIR.0b013e31826e1058\n                    \n                  .","journal-title":"Circulation"},{"key":"247_CR44","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327. \n                    http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1609324%0A\n                    \n                  . \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28273028\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"247_CR45","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340. \n                    http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2015.64.8899\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"247_CR46","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1002\/cncr.24504","volume":"115","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, Pasquini R, L\u00e9vy V, Jootar S, Holowiecki J, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer. 2009;115:4136\u201347. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19536906\n                    \n                  .","journal-title":"Cancer"},{"key":"247_CR47","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","volume":"125","author":"J Wang","year":"2015","unstructured":"Wang J, Shen Z-X, Saglio G, Jin J, Huang H, Hu Y, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015;125:2771\u20138. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25766724\n                    \n                  .","journal-title":"Blood"},{"key":"247_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/bjh.14829","volume":"179","author":"TP Hughes","year":"2017","unstructured":"Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, et al. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. Br J Haematol. 2017;179:219\u201328. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28699641\n                    \n                  .","journal-title":"Br J Haematol"},{"key":"247_CR49","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1016\/S2352-3026(16)30167-3","volume":"3","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, et al. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016;3:e581\u201391. \n                    http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352302616301673\n                    \n                  .","journal-title":"Lancet Haematol"},{"key":"247_CR50","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim D-W, Kantarjian HM, Br\u00fcmmendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486\u201392. \n                    http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2011.38.7522\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"247_CR51","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2017","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim D-W, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2017;36:231\u2013237. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29091516\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"247_CR52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner G-H, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533\u20139.","journal-title":"Am J Hematol"},{"key":"247_CR53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","volume":"12","author":"A Quint\u00e1s-Cardama","year":"2012","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337\u201340. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22633167\n                    \n                  .","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"247_CR54","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075\u201388. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23190221\n                    \n                  .","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0247-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0247-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0247-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:35:44Z","timestamp":1684618544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0247-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0247-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"10 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DHD has received a grant from Novartis. JHL has received honoraria, been on the advisory boards, and has received research funding from Novartis, BMS, Pfizer, and Ariad. NA declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}